.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,372,195

« Back to Dashboard

Details for Patent: 6,372,195

Title: Mixed gas microbubble compositions
Abstract:A microbubble preparation formed of a plurality of microbubbles comprising a first gas and a second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ratio of from about 1:100 to about 1000:1, and wherein the first gas has a vapor pressure of at least about (760-x) mm Hg at 37.degree. C., where x is the vapor pressure of the second gas at 37.degree. C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37.degree. C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; kits for preparing microbubbles; and methods for using such microbubbles as ultrasound contrast agents.
Inventor(s): Schutt; Ernest G. (San Diego, CA), Evitts; David P. (La Jolla, CA), Kinner; Rene Alta (San Diego, CA), Anderson; Charles David (Lebanon, NJ), Weers; Jeffry G. (San Diego, CA)
Assignee: Alliance Pharmaceutical Corp. (San Diego, CA)
Filing Date:Jan 17, 1997
Application Number:08/786,402
Claims:1. An injectable ultrasound contrast medium comprising:

(a) biocompatible at body temperature gaseous substances which, when in suspension in an aqueous carrier liquid containing surfactants, additives, and stabilizers, provide contrast agents for ultrasound echocardiography, wherein:

(b) the medium is a mixture which contains a modifier gas A and the balance of the mixture is an osmotic agent gas B;

(c) the ratio of gas A to gas B is 200:1 to 3:2 by volume; and

(d) gas B has a water solubility of not more than about 0.5 mM at 25.degree. C. and one atmosphere and an average molecular weight at least about 4 times that of gas A.

2. An injectable ultrasound contrast medium comprising:

(a) biocompatible at body temperature gaseous substances which, when in suspension in an aqueous carrier liquid containing surfactants, additives, and stabilizers, provide contrast agents for ultrasound echocardiography, wherein:

(b) the medium is a mixture which contains a modifier gas A and the balance of the mixture is an osmotic agent gas B;

(c) the ratio of gas A to gas B is 738:22 to 3:2 by volume; and

(d) gas B is selected from the group consisting of fluorocarbons, CCl.sub.2 F.sub.2, CHClF.sub.2, N(C.sub.2 F.sub.5).sub.3, N(C.sub.3 F.sub.7).sub.3, and mixtures thereof.

3. The ultrasound contrast medium of claim 1 wherein gas B is a fluorocarbon biocompatible gas.

4. The ultrasound contrast medium of claim 3 wherein the fluorocarbon biocompatible gas is selected from the group consisting of CF.sub.4, C.sub.3 F.sub.8, C.sub.4 F.sub.8, C.sub.4 F.sub.10, C.sub.5 F.sub.10, C.sub.5 F.sub.12, and mixtures thereof.

5. The ultrasound contrast medium of claim 4 wherein the fluorocarbon gas is octafluorocyclobutane.

6. The ultrasound contrast medium of claim 2 wherein gas A is selected from the group consisting of air, oxygen, nitrogen, carbon dioxide, and mixtures thereof.

7. An injectable ultrasound contrast agent comprising:

(a) a suspension of gas filled microbubbles or microballoons in a physiologically acceptable aqueous carrier comprising surfactants, additives, and stabilizers, wherein:

(b) the gas is a gas mixture containing a biocompatible gas A and the balance of the mixture is a biocompatible gas B;

(c) the ratio of gas A to gas B is 200:1 to 3:2 by volume; and

(d) gas B has a water solubility of not more than about 0.5 mM at 25.degree. C. and one atmosphere and an average molecular weight at least about 4 times that of gas A.

8. An injectable ultrasound contrast agent comprising:

(a) a suspension of gas filled microbubbles or microballoons in a physiologically acceptable aqueous carrier comprising surfactants, additives, and stabilizers, wherein:

(b) the gas is a gas mixture containing a biocompatible gas A and the balance of the mixture is a biocompatible gas B;

(c) the ratio of gas A to gas B is 738:22 to 3:2 by volume; and

(d) gas B is selected from the group consisting of fluorocarbons, CCl.sub.2 F.sub.2, CHClF.sub.2, N(C.sub.2 F.sub.5).sub.3, N(C.sub.3 F.sub.7).sub.3, and mixtures thereof.

9. The ultrasound contrast agent of claim 7 wherein gas B is a fluorocarbon biocompatible gas.

10. The ultrasound contrast agent of claim 9 wherein the fluorocarbon biocompatible gas is selected from the group consisting of CF.sub.4, C.sub.3 F.sub.8, C.sub.4 F.sub.8, C.sub.4 F.sub.10, C.sub.5 F.sub.10, C.sub.5 F.sub.12, and mixtures thereof.

11. The ultrasound contrast agent of claim 9 wherein gas A is selected from the group consisting of air, oxygen, nitrogen, carbon dioxide, and mixtures thereof.

12. The ultrasound contrast agent of claim 10 wherein the surfactants comprise at least one film forming surfactant and, optionally, stabilizers.

13. The ultrasound contrast agent of claim 12 wherein the film forming surfactant is a phospholipid.

14. The ultrasound contrast agent of claim 7 wherein the surfactant is polyethylene oxide sorbitan fatty acid ester or sorbitol.

15. A dry formulation comprising:

(a) surfactants, additives, and stabilizers stored under a mixture of substances which at body temperature are biocompatible gases, wherein:

(b) at least one of the biocompatible gases is a fluorine-containing gas having a water solubility of not more than about 0.5 mM at 25.degree. C. and one atmosphere and an average molecular weight at least about 4 times that of air, oxygen, nitrogen, carbon dioxide or mixtures thereof;

(c) the balance is air, oxygen, nitrogen, carbon dioxide, or mixtures thereof; and

(d) the ratio of said air, oxygen, nitrogen, carbon dioxide, or mixtures thereof to said fluorine-containing gas is 200:1 to 3:2 by volume.

16. A dry formulation comprising:

(a) surfactants, additives, and stabilizers stored under a mixture of substances which at body temperature are biocompatible gases, wherein:

(b) at least one of the biocompatible gases is a fluorocarbon gas;

(c) the balance is air, oxygen, nitrogen, carbon dioxide, or mixtures thereof; and

(d) the ratio of said air, oxygen, nitrogen, carbon dioxide, or mixtures thereof to said fluorine-containing gas is 738:22 to 3:2 by volume.

17. A two component kit comprising:

(a) as the first component, a dry formulation of surfactants, additives, and stabilizers stored under a mixture of substances which at body temperature are gases; and,

(b) as the second component, a physiologically acceptable carrier liquid which, when admixed with the first component, provides, as a suspension of the two components, an ultrasound contrast agent, wherein:

(c) at least one of the gases in the mixture is a gas having a water solubility of not more than about 0.5 mM at 25.degree. C. and one atmosphere and an average molecular weight of at least about 4 times that of air, oxygen, nitrogen, carbon dioxide, or mixtures thereof;

(d) the balance is air, oxygen, nitrogen, carbon dioxide, or mixtures thereof; and

(e) the ratio of said air, oxygen, nitrogen, carbon dioxide, or mixtures thereof to said gas having a water solubility of not more than about 0.5 mM at 25.degree. C. and one atmosphere and an average molecular weight of at least about 4 times that of air, oxygen, nitrogen, carbon dioxide, or mixtures thereof is 200:1 to 3:2 by volume.

18. A two component kit comprising:

(a) as the first component, a dry formulation of surfactants, additives, and stabilizers stored under a mixture of substances which at body temperature are gases; and,

(b) as the second component, a physiologically acceptable carrier liquid which, when admixed with the first component, provides, as a suspension of the two components, an ultrasound contrast agent wherein:

(c) at least one of the gases in the mixture is a fluorocarbon biocompatible gas;

(d) the balance is air, oxygen, nitrogen, carbon dioxide, or mixtures thereof; and

(e) the ratio of said air, oxygen, nitrogen, carbon dioxide, or mixtures thereof to said gas having a water solubility of not more than about 0.5 mM at 25 .degree. C. and one atmosphere and an average molecular weight of at least about 4 times that of air, oxygen, nitrogen, carbon dioxide, or mixtures thereof is 200:1 to 3:2 by volume.

19. The two component kit of claim 18 wherein the fluorocarbon biocompatible gas is selected from the group consisting of CF.sub.4, C.sub.3 F.sub.8, C.sub.4 F.sub.8, C.sub.4 F.sub.10, C.sub.5 F.sub.10, C.sub.5 F.sub.12, and mixtures thereof.

20. A method of imaging organs in a living body, said method comprising the steps of:

(1) administering to said body an ultrasound contrast agent comprising a suspension of gas filled microbubbles or microballoons in a physiologically acceptable aqueous carrier comprising surfactants, additives, and stabilizers, wherein:

(a) the gas is a gas mixture containing a biocompatible gas A and a biocompatible gas B;

(b) gas B has a water solubility of not more than about 0.5 mM at 25.degree. and one atmosphere and an average molecular weight at least about 4 times that of gas A, and

(c) the ratio of gas A to gas B is 200:1 to 3:2 by volume; and

(2) subjecting said body to ultrasound therapy.

21. A method of imaging organs in a living body, said method comprising the steps of:

(1) administering to said body an ultrasound contrast agent comprising a suspension of gas filled microbubbles or microballoons in a physiologically acceptable aqueous carrier comprising surfactants, additives, and stabilizers, wherein:

(a) the gas is a gas mixture containing a biocompatible gas A and a biocompatible gas B;

(b) gas B is a fluorocarbon; and

(c) the ratio of gas A to gas B is 738:22 to 3:2 by volume; and

(2) subjecting said body to ultrasound therapy.

22. The method of claim 21 wherein the flourocarbon biocompatible gas is selected from the group consisting of CF.sub.4, C.sub.3 F.sub.8, C.sub.4 F.sub.8, C.sub.4 F.sub.10, C.sub.5 F.sub.10, C.sub.5 F.sub.12, and mixtures thereof.

23. The method of claim 21 wherein gas A is selected from the group consisting of air, oxygen, nitrogen, carbon dioxide, and mixtures thereof.

24. The method of claim 21 wherein the surfactants comprise at least one film forming surfactant and, optionally, stabilizers.

25. The method of claim 24 wherein the film forming surfactant is a phospholipid.

26. The method of claim 20 wherein the surfactant is a polyethylene oxide sorbitan fatty acid ester or sorbitol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc